Rebecca McCrary v. Eli Lilly and Company, et al
| In re: DARVOCET, DARVON, AND PROPOXYPHENE PRODUCTS LIABILITY LITIGATION |
| REBECCA MCCRARY |
| ELI LILLY AND COMPANY, formerly sued as Eli Lilly & Company, Inc., XANODYNE PHARMACEUTICALS, INC., QUALITEST PHARMACEUTICALS, INC., VINTAGE PHARMACEUTICALS, INC., PROPST DISTRIBUTION, INC., BRENN DISTRIBUTION, INC., BRENN MANUFACTURING, INC., GENERICS INTERNATIONAL (US), INC., GENERICS BIDCO I, LLC, GENERICS BIDCO II, LLC, GENERICS INTERNATIONAL (US PARENT), INC., COVIDIEN, INC., MALLINCKRODT, INC., TEVA PHARMACEUTICALS, USA, INC., MYLAN PHARMACEUTICALS, INC., MYLAN, INC., WATSON PHARMACEUTICALS, INC., ENDO PHARMACEUTICALS, INC. and ENDO PHARMACEUTICALS HOLDINGS, INC. |
| 12-5596 |
| May 24, 2012 |
| U.S. Court of Appeals, Sixth Circuit |
| P.I.: Product Liability |
Opinions
We have the following opinions for this case:
| Description |
|---|
 Rebecca McCrary v. Eli Lilly and Company
|
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
